Genomic Biomarkers Market by Product & Service (Consumable, Software), Type (Safety, Efficacy), Technology (NGS, PCR), Disease (Cancer, Infectious) -Forecast to 2030

The global genomic biomarkers market is set for robust growth as precision medicine reshapes diagnostics and therapeutic decision-making across healthcare and life sciences. According to the latest industry analysis, the market is projected to expand from USD 29.00 billion in 2025 to USD 50.31 billion by 2030, registering a compound annual growth rate (CAGR) of 11.6% during the forecast period.

This growth underscores a fundamental shift in how diseases are detected, monitored, and treated, with genomic biomarkers increasingly guiding clinical decisions, drug development strategies, and personalized treatment pathways.

Market Overview and Scope

The report, “Genomic Biomarkers Market by Product & Service (Consumable, Software), Type (Safety, Efficacy), Technology (NGS, PCR), Disease (Cancer, Infectious) – Forecast to 2030,” provides a comprehensive evaluation of market dynamics. It features 708 market data tables and 56 figures across 506 pages, offering deep insights into technology adoption, disease applications, and regional trends.

The genomic biomarkers market is gaining momentum due to the growing use of genomic testing in oncology, rare diseases, and inherited disorders, coupled with rapid advancements in polymerase chain reaction (PCR) and next-generation sequencing (NGS) technologies. These innovations are enabling faster, more accurate, and more scalable biomarker discovery and validation.

Technology Trends: Why NGS Leads the Market

By technology, next-generation sequencing (NGS) accounted for the largest share of the genomic biomarkers market in 2024. What makes NGS critical now is its ability to analyze hundreds of genes and complex molecular signatures in a single run. Hospitals, cancer centers, and pharmaceutical companies increasingly rely on NGS for comprehensive tumor profiling, minimal residual disease detection, and the identification of prognostic and predictive biomarkers.

As precision oncology and multi-gene panel testing become standard practice, NGS continues to outperform traditional methods in terms of depth, efficiency, and clinical relevance.

End-User Insights: Pharma and Biotech Drive Demand

By end users, pharmaceutical and biotechnology companies emerged as the fastest-growing segment in 2024. These organizations depend on genomic biomarkers throughout the drug development lifecycle—from target identification and patient stratification to treatment response monitoring and companion diagnostics development.

The consistent and high-volume demand generated by biomarker-driven clinical trials highlights how genomic insights are becoming integral to reducing drug development risk, improving trial outcomes, and accelerating regulatory approvals.

Regional Outlook: North America Maintains Market Leadership

Regionally, North America accounted for the largest share of the genomic biomarkers market in 2024. This dominance is driven by a strong ecosystem of academic medical centers, cancer institutes, and commercial laboratories that have rapidly adopted NGS-based testing, liquid biopsies, and companion diagnostics.

Favorable reimbursement frameworks, major government initiatives such as the Cancer Moonshot, and sustained investment from pharmaceutical and biotechnology companies in biomarker-led clinical research continue to reinforce North America’s leadership in genomic biomarker revenues.

Competitive Landscape

The genomic biomarkers market is characterized by the presence of established global players and innovation-driven companies. Key participants include Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Illumina, Inc. (US), QIAGEN (Germany/Netherlands), Bio-Rad Laboratories, Inc. (US), Agilent Technologies, Inc. (US), Eurofins Scientific (Luxembourg), and Quanterix (US). These organizations are actively investing in technology advancements, assay development, and strategic collaborations to strengthen their market positions.

Why This Market Matters Now

As healthcare systems worldwide move toward personalized, data-driven medicine, genomic biomarkers are becoming indispensable for improving diagnostic accuracy, optimizing therapies, and enhancing patient outcomes. For C-suite executives and strategic decision-makers, this market signals sustained opportunities across diagnostics, drug development, software platforms, and laboratory services.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/genomic-biomarkers-market-48860286.html

 

Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Genomic Biomarkers Market Poised for Strong Expansion as Precision Medicine Accelerates Worldwide

Information contained on this page is provided by an independent third-party content provider. XPRMedia and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected]